You are viewing an old version of this page. View the current version.

Compare with Current View Page History

« Previous Version 5 Next »

Project Scope

The increasing interest/pressure to include results based on real world data as part of regulated Clinical Trial Submissions and similar research initiatives is testing how current regulatory and good practice requirements can incorporate these results into submissions. Whilst specific projects have successfully addressed these issues, RWE guidelines or points for consideration are not yet formalised. This project aims to focus on the issues within Real World Evidence and develop a White Paper which establishes a range of areas that need to be considered/impact the use of RWE in support of regulated clinical trial submissions

Project LeadsEmail
David Hood 
Sangeeta Bhattacharya  
david.hood@pfizer.com
SBhatt11@its.jnj.com
Project MembersCompany
Adam ReichIQVIA
Andy SteenEDJAnalytics
Anil SekhariSekharico Informatics
Aldir Medeiros FilhoIndustry
Berber SnoeijerClinline
Bhanu KannanFDA
CHARAN KUMAREphicacy
Claudi JimenezSyneos Health
Corey YoungEDJAnalytics
Diego SaldanaRoche
Elizabeth MerrallS-Cubed
Hao ChenPfizer
Jeff AbolafiaPinnacle21
Jingwen ZhangIndustry
Kiichiro ToyoizumiShionogi
Lisa KangPharma Essentia
Lisa LinFDA
Project MembersCompany
Marko ZivkovicGenesis
Michael MartinecRoche
Nicole ThorneJNJ
Nurcan Coskun Industry
Oluseun ShittuGlaxoSmithKline
Paul MurraySAS
Pranab MitraMerck
Rachel BowmanLoxley Analytics
Rosa Bianca GalloThe Hyve
Scott BahlavooniIndustry
Siddharth ArthiZifornd
Susan EatonBiogen
Susan OlsonEDJAnalytics
Susheel ArkalaMMS Holdings
Shaojun SongYitu Technology
Trisha SimpsonUCB
Yixun WuSyneoshealth
Ingeborg HoltIMB
Sadchla MascaryPfizer
Swapna KavetiIndustry
  • No labels